The announcement of a substantial cash balance and an extended cash runway is a positive signal to investors, indicating that Entrada Therapeutics is well-funded for its current and future projects. This reduces the immediate risk of financial distress or the need for dilutive financing, which can be reassuring for investors and potentially positive for the stock price in the short term.